Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER
BIOBADASER Group.
Carmona L, Gomez-Reino JJ, BIOBADASER Group. 2006. Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. Arthritis Res Ther 8: R72.
Retention rates of tumor necrosis factor blockers in daily practice in 770 rheumatic patients
Duclos M, Gossec L, Ruyssen-Witrand A, Salliot C, Luc M, Guignard S, Dougados M,. 2006. Retention rates of tumor necrosis factor blockers in daily practice in 770 rheumatic patients. J Rheumatol 33: 2433-2438.
Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival
et al.
Flouri I, Markatseli TE, Voulgari PV, Boki KA, Papadopoulos I, Settas L, Zisopoulos D, Skopouli FN, Iliopoulos A, Bertsias GK, et al. 2014. Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: low rates of remission and 5-year drug survival. Semin Arthritis Rheum 43: 447-457.
Switching TNF antagonists in patients with chronic arthritis: An observational study of 488 patients over a four-year period
BIOBADASER Group.
Gomez-Reino JJ, Carmona L, BIOBADASER Group. 2006. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther 8: R29.
Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry
et al.
Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, Kollerup G, Linde L, Lindegaard HM, Poulsen UE, et al. 2010. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 62: 22-32.
Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: Results from a large UK national cohort study
British Society for Rheumatology Biologics Register.
Hyrich KL, Lunt M, Watson KD, Symmons DPM, Silman AJ, British Society for Rheumatology Biologics Register. 2007. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 56: 13-20.
Longterm retention of tumor necrosis factor-α inhibitor therapy in a large Italian cohort of patients with rheumatoid arthritis from the GISEA registry: An appraisal of predictors
et al.
Iannone F, Gremese E, Atzeni F, Biasi D, Botsios C, Cipriani P, Ferri C, Foschi V, Galeazzi M, Gerli R, et al. 2012. Longterm retention of tumor necrosis factor-α inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors. J Rheumatol 39: 1179-1184.
TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice
Marchesoni A, Zaccara E, Gorla R, Bazzani C, Sarzi-Puttini P, Atzeni F, Caporali R, Bobbio-Pallavicini F, Favalli EG,. 2009. TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann N Y Acad Sci 1173: 837-846.